Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 ...
Investing.com - UBS has reiterated its Buy rating on ResMed (NYSE:RMD) with a price target of $345.00, according to a recent analyst note. The stock currently trades at $261.13, representing a ...
A sleep apnea implant sends a signal to move the tongue and keep the airway open while you sleep. To qualify for the implant, you must have a BMI of less than 35 and cannot tolerate a CPAP device. The ...
Sleep has become a battleground for technology firms, insurers and health providers, with significant money riding on what happens overnight. Once treated as a personal habit, sleep now features in ...
SAN FRANCISCO – Resmed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results